EP3398947A4 - Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés - Google Patents
Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés Download PDFInfo
- Publication number
- EP3398947A4 EP3398947A4 EP16881301.2A EP16881301A EP3398947A4 EP 3398947 A4 EP3398947 A4 EP 3398947A4 EP 16881301 A EP16881301 A EP 16881301A EP 3398947 A4 EP3398947 A4 EP 3398947A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- composition
- well
- application
- compound containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511028799 | 2015-12-31 | ||
| CN201610516637 | 2016-07-01 | ||
| CN201610877404 | 2016-09-30 | ||
| PCT/CN2016/113887 WO2017114512A1 (fr) | 2015-12-31 | 2016-12-30 | Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP3398947A1 EP3398947A1 (fr) | 2018-11-07 |
| EP3398947A4 true EP3398947A4 (fr) | 2019-08-07 |
| EP3398947B1 EP3398947B1 (fr) | 2024-08-28 |
| EP3398947C0 EP3398947C0 (fr) | 2024-08-28 |
Family
ID=59224673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16881301.2A Active EP3398947B1 (fr) | 2015-12-31 | 2016-12-30 | Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10662186B2 (fr) |
| EP (1) | EP3398947B1 (fr) |
| JP (1) | JP6663021B2 (fr) |
| CN (1) | CN106928219B (fr) |
| ES (1) | ES2994614T3 (fr) |
| WO (1) | WO2017114512A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106928219B (zh) | 2015-12-31 | 2021-08-20 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108727368B (zh) * | 2017-04-14 | 2022-05-03 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、其制备方法、中间体、组合物和应用 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
| GEP20227433B (en) * | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| CN111454260B (zh) * | 2020-05-25 | 2023-02-28 | 贵州大学 | 一类含异丙醇胺亚结构的1,2,3,4-四氢-β-咔啉类化合物及其制备方法和应用 |
| WO2022113003A1 (fr) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Inhibiteurs de cdk |
| WO2022149057A1 (fr) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Inhibiteurs de cdk |
| CN114907343A (zh) * | 2021-02-10 | 2022-08-16 | 上海医药集团股份有限公司 | 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途 |
| CN115124525A (zh) * | 2021-03-26 | 2022-09-30 | 上海医药集团股份有限公司 | 含氮稠杂环化合物的盐的晶型及其制备方法和应用 |
| CN115650968B (zh) * | 2022-12-27 | 2023-03-21 | 英矽智能科技(上海)有限公司 | 作为cdk选择性抑制剂的新型哒嗪酮化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (fr) * | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Inhibiteurs de protéine kinases |
| WO2016015604A1 (fr) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005939A (es) * | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2654670A1 (fr) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Nouveaux composes |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| CN102531949A (zh) * | 2010-12-29 | 2012-07-04 | 中国医学科学院药物研究所 | 一种取代苯甲酰胺类化合物及其制备方法和用途 |
| CN103304572A (zh) * | 2012-03-09 | 2013-09-18 | 上海医药集团股份有限公司 | 一类3-氰基喹啉类化合物及其药用组合物和应用 |
| CN106188038A (zh) | 2015-06-01 | 2016-12-07 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| CN106928219B (zh) | 2015-12-31 | 2021-08-20 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 |
-
2016
- 2016-12-30 CN CN201611265083.2A patent/CN106928219B/zh active Active
- 2016-12-30 WO PCT/CN2016/113887 patent/WO2017114512A1/fr not_active Ceased
- 2016-12-30 US US16/067,158 patent/US10662186B2/en active Active
- 2016-12-30 EP EP16881301.2A patent/EP3398947B1/fr active Active
- 2016-12-30 JP JP2018534536A patent/JP6663021B2/ja active Active
- 2016-12-30 ES ES16881301T patent/ES2994614T3/es active Active
-
2020
- 2020-04-15 US US16/848,942 patent/US10988476B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (fr) * | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Inhibiteurs de protéine kinases |
| WO2016015604A1 (fr) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations |
Non-Patent Citations (2)
| Title |
|---|
| SÁNCHEZ-MARTÍNEZ CONCEPCIÓN ET AL: "Cyclin dependent kinase (CDK) inhibitors as anticancer drugs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 17, 6 June 2015 (2015-06-06), pages 3420 - 3435, XP029249423, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.05.100 * |
| See also references of WO2017114512A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3398947A1 (fr) | 2018-11-07 |
| WO2017114512A1 (fr) | 2017-07-06 |
| CN106928219A (zh) | 2017-07-07 |
| US20190010153A1 (en) | 2019-01-10 |
| EP3398947B1 (fr) | 2024-08-28 |
| EP3398947C0 (fr) | 2024-08-28 |
| ES2994614T3 (en) | 2025-01-27 |
| US20200239470A1 (en) | 2020-07-30 |
| US10662186B2 (en) | 2020-05-26 |
| US10988476B2 (en) | 2021-04-27 |
| CN106928219B (zh) | 2021-08-20 |
| JP2019500389A (ja) | 2019-01-10 |
| JP6663021B2 (ja) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3398947A4 (fr) | Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés | |
| EP3424928A4 (fr) | Composé hétérocyclique azoté, procédé de préparation, intermédiaire, composition et utilisation | |
| EP3349587A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3353841A4 (fr) | Procédé de préparation et d'application de composites de carbone-sélénium | |
| EP2921480A4 (fr) | Composé hétérocyclique contenant de l'azote | |
| EP2947084A4 (fr) | Composé hétérocyclique à cinq et six chaînons, procédé de préparation, composition pharmaceutique et application associés | |
| EP2687507A4 (fr) | Composé hétérocyclique condensé contenant de l'azote | |
| EP3322434A4 (fr) | Pièce d'habillement technique en soie et procédés de préparation | |
| EP3517535A4 (fr) | Composé hétérocyclique substitué par un alcynyle, son procédé de préparation et son utilisation médicale | |
| EP2821402A4 (fr) | Composé hétérocyclique aromatique contenant de l'azote | |
| EP3006445A4 (fr) | Hydrogénosulfate d'inhibiteur de janus kinase (jak) et son procédé de préparation | |
| EP2940024A4 (fr) | Composé de benzoxazine et d'oxazolidinone, son procédé de préparation et son application | |
| EA201200098A1 (ru) | Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия | |
| EP3424924A4 (fr) | Composé d'urée, son procédé de préparation et son utilisation médicale | |
| BR112018005208A2 (pt) | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana | |
| EP3498716A4 (fr) | Composé thiénopyrimidine, son procédé de préparation, composition pharmaceutique et applications associées | |
| EP3012256A4 (fr) | Composé hétérocyclique de benzimidazole-2-pipérazine, composition pharmaceutique le contenant, procédé de préparation et d'utilisation associé | |
| EP2927214A4 (fr) | Composé hétérocyclique contenant de l'azote | |
| EP3733665A4 (fr) | Composé cyclique à six chaînons contenant de l'azote | |
| MA37650A1 (fr) | Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| EP3643311A4 (fr) | Composé d'acide tétramique 4-oxo-alkylé, son procédé de préparation et son utilisation | |
| EP3447054A4 (fr) | Composé et procédé pour sa préparation, composition et application correspondantes | |
| EP3281945A4 (fr) | Dérivé d'acide phillygénine glucuronique, son procédé de préparation et son application | |
| EP3647306A4 (fr) | Composé d'acide tétramique 4-oxo-alkylé et son procédé de préparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180724 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190704 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20190628BHEP Ipc: A61K 31/4375 20060101ALI20190628BHEP Ipc: A61K 31/519 20060101ALI20190628BHEP Ipc: C07D 471/04 20060101AFI20190628BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210407 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240426 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016089175 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20240920 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20241014 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241128 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241129 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241228 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2994614 Country of ref document: ES Kind code of ref document: T3 Effective date: 20250127 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241128 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241128 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241128 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241228 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241129 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 9 Effective date: 20241227 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240828 |
|
| 26N | No opposition filed |
Effective date: 20250530 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241230 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260101 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20251219 Year of fee payment: 10 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 10 Effective date: 20251230 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20260130 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20260101 Year of fee payment: 10 |